KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer

BACKGROUND: KRAS mutations are predictive markers for the efficacy of anti-EGFR antibody therapies in patients with metastatic colorectal cancer. Although the mutational status of KRAS is reportedly highly concordant between primary and metastatic lesions, it is not yet clear whether genotoxic chemo...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kawamoto, Y, Tsuchihara, K, Yoshino, T, Ogasawara, N, Kojima, M, Takahashi, M, Ochiai, A, Bando, H, Fuse, N, Tahara, M, Doi, T, Esumi, H, Komatsu, Y, Ohtsu, A
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2012
Sujets:
Molecular Diagnostics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3394966/
https://ncbi.nlm.nih.gov/pubmed/22617127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.218
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires